Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors

Area of Science:

• Immunology
• Metabolic pathways
• Biochemistry

Background:

• The tryptophan (TRP) to kynurenine (KYN) metabolic pathway is a critical regulator of innate and adaptive immunity.
• This pathway, driven by indoleamine-2,3-dioxygenase and TRP-2,3-dioxygenase, plays a role in cancer immunity, autoimmunity, infection, transplant rejection, and allergy.

Purpose of the Study:

• To review recent insights into the regulation of TRP metabolism and its downstream effectors.
• To discuss the therapeutic potential of targeting the TRP metabolism pathway at multiple levels.

Main Methods:

• Review of recent scientific literature on tryptophan metabolism.
• Analysis of preclinical models and clinical trial data for TRP pathway inhibitors.

Main Results:

• The TRP-KYN pathway is a key immune tolerance mechanism active in various diseases.
• Indoleamine-2,3-dioxygenase inhibitors are in clinical trials for cancer immunotherapy.
• Understanding downstream mediators like the aryl hydrocarbon receptor expands therapeutic intervention points.

Conclusions:

• Targeting the TRP metabolism pathway offers significant therapeutic potential across a range of immune-related disorders.
• Further research into TRP metabolism regulation and downstream effectors will unlock new intervention strategies.